Close
  Indian J Med Microbiol
 

Figure 4: Time course of PEVAC lesion treatment. At baseline, significant CME was noted (a) along with the PEVAC lesion (purple arrow, b). A minimal change was noted in CME (c) and PEVAC lesion (red arrow, d) after three doses of intravitreal ranibizumab injections were given. After intravitreal dexamethasone implant was given, there was complete resolution of CME (e), but the PEVAC lesion persisted (blue arrow, f) at 1 and 3 months, respectively. However, the patient presented with a recurrence of CME at 4 months (g), with the persistence of PEVAC lesion (yellow arrow, h). CME = cystoid macular edema, PEVAC = perifoveal exudative vascular anomalous complex, SD-OCT = spectral domain optical coherence tomography

Figure 4: Time course of PEVAC lesion treatment. At baseline, significant CME was noted (a) along with the PEVAC lesion (purple arrow, b). A minimal change was noted in CME (c) and PEVAC lesion (red arrow, d) after three doses of intravitreal ranibizumab injections were given. After intravitreal dexamethasone implant was given, there was complete resolution of CME (e), but the PEVAC lesion persisted (blue arrow, f) at 1 and 3 months, respectively. However, the patient presented with a recurrence of CME at 4 months (g), with the persistence of PEVAC lesion (yellow arrow, h). CME = cystoid macular edema, PEVAC = perifoveal exudative vascular anomalous complex, SD-OCT = spectral domain optical coherence tomography